Teva Pharmaceutical launches Fexofenadine HCl and Pseudoephedrine HCl tablets

Download PDF Copy

Nov 4 2009

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today the commercial launch of Fexofenadine Hydrochloride 60 mg and Pseudoephedrine Hydrochloride 120 mg Extended-Release Tablets, the same as the sanofi-aventis U.S. allergy treatment Allegra-D® 12 Hour (fexofenadine HCl 60 mg and pseudoephedrine HCl 120 mg) Extended-Release Tablets. Teva's product is an alternative to the brand product, which had annual sales of approximately $293 million in the United States for the twelve months that ended June 30, 2009, based on IMS sales data.

As the first company to file an ANDA containing a paragraph IV certification for this product, Teva has been awarded a 180-day period of marketing exclusivity in the U.S.

Teva is distributing the product, under a license agreement entered into between Teva's subsidiary Barr Pharmaceuticals, Inc. and sanofi-aventis U.S. Allegra-D is a registered trademark of sanofi-aventis U.S.

Source:

Teva Pharmaceutical Industries Ltd.,

Posted in: Pharmaceutical News

Comments (0)

Download PDF Copy

Suggested Reading

How do common painkillers drive stronger E. coli resistance?

New treatment approach developed to prevent lupus nephritis

WHO expands global network of trusted medical product regulators

Gene editing restores hearing and balance in adult mice with DFNA41 deafness

Mentavi study validates first fully digital diagnostic pathway for adult ADHD

University of Vienna team develops method to measure molecular charges

Targeting gut signaling protein may protect against alcohol-related liver damage

Mushrooms deliver nutrition medicine and sustainability solutions in one package

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.